Enteral Feeding Formulas Market Key Factors Boosting Segment Growth By 2028

 Enteral Feeding Formulas Industry Overview

The global enteral feeding formulas market size is expected to reach USD 9.3 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.9% from 2021 to 2028. The growing prevalence of chronic diseases such as cancer, stroke, multiple sclerosis, dementia, chronic liver disease, Chronic Obstructive Pulmonary Disease (COPD), and diabetes is projected to drive the demand for products that support patients with oral intake issues. In addition, the rise in preterm births is one of the significant factors boosting the demand for enteral feeding formulas to meet the nutritional requirements of newborns.

Based on product, the standard formulas segment dominated the market and accounted for the largest revenue share of 54.0% in 2020. This high share is attributable to the availability of a vast variety of standard formulas coupled with increased demand for low-cost nutrient formulations. In addition, the demand with respect to standard tube feeds is significant among the volume-sensitive patients or the patients on fluid restrictions. Such conditions include renal failure, congestive heart failure, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).

In 2020, based on flow type, the intermittent feeding flow type segment accounted for the highest revenue share in the market because intermittent feeding has shown better tolerance in patients as compared to bolus feeding. Moreover, this type of feeding does not require feeding pumps, which is helpful in allowing greater mobility in between the feedings. This is expected to increase its adoption among the hospital as well as homecare settings, thereby affirmatively impacting the segment growth.

In 2020, based on stage, the adults' segment accounted for the highest revenue share of 88.4% in the market. The segment is projected to witness the fastest CAGR over the forecast period. The rising adoption of tube feeds in adults is one of the crucial factors driving the growth. In addition, the availability of large number of tube feeds or products for adults on a commercial level also contributes to the large share held by the segment. Glucerna, Osmolite, TwoCal, Vital, Promote, and Jevity are some of the popular brands by Abbott Nutrition for adults.

Based on indications, other indications, followed by cancer care accounted for the largest share in terms of revenue in 2020. The increasing prevalence of cancer and other health conditions associated with cancer is likely to promote market growth. For instance, according to GLOBOCON 2020, there were around 19.3 million new cases of cancer worldwide in 2020. Europe accounted for about 23.4% of total cancer cases and Asia had the highest population suffering from cancer, which was about 60%.

In 2020, based on end user, the homecare segment accounted for the highest revenue share in the market and this segment is projected to witness the fastest CAGR over the forecast period. The increasing number of patients that receive home enteral feeding due to growing awareness about complete and balanced nutrition is one of the key factors contributing to the growth of this segment. For instance, according to a recent survey conducted in the U.K., there were 187 patients on home enteral tube feeding out of the total 257 patients. This suggested that approximately 72% of patients were on home enteral tube feeding.


Enteral Feeding Formulas
Market Segmentation

Grand View Research has segmented the global enteral feeding formulas market based on product, flow type, stage, indications, end-user, and region:

Based on the Product Insights, the market is segmented into Standard formula, and Disease-specific formula.

  • Standard formulas dominated the market and accounted for the largest revenue share of 54.0% in 2020. This high share is attributable to the availability of a wide variety of standard formulas coupled with increased demand for low-cost nutrient formulations.
  • The disease specific formulas segment is anticipated to grow at the fastest rate during the forecast period. The high prevalence of chronic diseases, such as cancer, diabetes, and liver failure, is propelling the demand for disease-specific formulas.

 

Based on the Flow Type Insights, the market is segmented into Intermittent feeding flow, and Continuous feeding flow.

  • Intermittent feeding flow type accounted for the highest revenue share of 94.5% in the market. This is because intermittent feeding has shown better tolerance in patients as compared to bolus feeding. Moreover, this type of feeding does not require feeding pumps, which is helpful in allowing greater mobility in between the feedings.
  • The continuous feeding flow type segment is expected to witness the highest CAGR over the forecast period. The lower feeding rate of continuous feeding flow as compared to intermittent feeding is one of the major factors responsible for the lucrative growth of the segment. Continuous tube feeding is recommended for critically ill patients suffering from conditions such as respiratory failure, severe burns, and cancer.

 

Based on the Stage Insights, the market is segmented into Adult, and Pediatric.

  • The adults' segment accounted for the highest revenue share of 88.4% in the market. The segment is projected to witness the fastest CAGR over the forecast period. The rising adoption of tube feeds in adults is one of the crucial factors driving the growth.
  • Increasing demand for tube feeds among pregnant women is also one of the major factors driving the market for the adult segment. In addition, pregnant women frequently suffer from hyperemesis gravidarum, which is categorized by severe vomiting and nausea, which may lead to a deficiency of vital nutrients and dehydration.

 

Based on the Indication Insights, the market is segmented into Alzheimer’s, Nutrition Deficiency, Cancer Care, Diabetes, Chronic Kidney Diseases, Orphan Diseases, Dysphagia, Pain Management, Malabsorption/GI Disorder/Diarrhea, and Others.

  • Others' segment dominated the market and accounted for the largest revenue share of 42.7% in 2020. The segment is followed by cancer care, which accounted for a significant share of 24.0% in terms of revenue in 2020. The increasing prevalence of cancer and other health conditions associated with cancer is likely to promote the growth of the segment.
  • Cancer weakens immunity and leads to loss of energy, which results in malnutrition in 40% to 80% of the cases. This affects the response to the treatment as well as increases treatment-related toxicity. Hence, to maintain nutrition and positive nitrogen balance, tube feeding is used, thereby fueling the market growth.

 

Based on the End-user Insights, the market is segmented into Hospitals, and Home Care.

  • The homecare segment accounted for the highest revenue share of 56.1% in the market. The segment is projected to witness the fastest CAGR over the forecast period. The increasing number of patients that receive home enteral feeding due to growing awareness about complete and balanced nutrition is one of the key factors contributing to the growth of this segment.
  • Rising awareness regarding enteral feeding formulas among home-based healthcare patients and increasing government intervention for educating the patient population with regards to the utilization of enteral feeding systems or pumps are some of the other factors boosting segment growth.

 

Enteral Feeding Formulas Regional Outlook

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

The market is characterized by the presence of leading players with strong product portfolios, global presence, and financial performance. For instance, Abbott, headquartered in the U.S. markets and sells its products in more than 150 countries across the globe. In addition, companies are strategically collaborating with other players in the market, in the form of mergers and partnerships, for leveraging their technological capabilities and expanding their product portfolios of enteral foods. Moreover, major players are continuously investing in R&D activities for the development of new products that cater to niche therapeutic areas with higher growth potential to gain a competitive edge. In addition, market entry is challenging for new players as space is dominated by major MNCs with high brand recognition. Some of the prominent players in the enteral feeding formulas market include:

  • Abbott
  • Danone SA
  • Fresenius Kabi
  • NestlĂ©
  • Victus, Inc.
  • Primus Pharmaceuticals, Inc.
  • Meiji Holdings. Co., Ltd.
  • Rickett Benckiser Group Plc.

 

Order a free sample PDF of the Enteral Feeding Formulas Market Intelligence Study, published by Grand View Research.

 

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

 

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com

Follow Us: LinkedIn | Twitter

Comments

Popular posts from this blog

What Are The Factors Driving The Reusable Water Bottle Market By 2030?

Farm Tire Market: Bias Tires Are Expected To Witness The Fastest Growth In Terms Of Revenue From 2021 To 2028

North America Tabletop Kitchen Products Market: Flatware Segment Is Projected To Register A Significant CAGR Of 5.1% From 2021 To 2028